Researchers have scheduled human tests on a third possible Ebola vaccine in response to the U.N.'s call to fast-track treatments for the worst known outbreak of the deadly virus in human history.
Johnson & Johnson said in a statement early Thursday it would begin human trials early next year of a vaccine derived from technologies created by Crucell N.V. of the Netherlands and the Danish biotech company Bavarian Nordic. "In light of the current emergency in West Africa and given the evident, huge unmet medical need, we are stepping up our efforts and accelerating the Ebola program," said Johan Van Hoof, global head of infectious disease and vaccine programs for Crucell.
GlaxoSmithKline has already said it will begin trials this month on its potential vaccine, and trials on a vaccine being developed by the Canadian government could begin later this year.
— M. Alex Johnson